Ad
related to: pfizer ex dividend date 2023
Search results
Results From The WOW.Com Content Network
Pfizer's current 5.73% dividend yield stands well above the S&P 500 average of 1.35%. ... The drugmaker is investing heavily in oncology following its $43 billion acquisition of Seagen in 2023 ...
With a lot of new drugs to sell, Pfizer expects adjusted earnings to reach a range between $2.15 and $2.35 per share this year, which is more than it needs to meet a dividend commitment currently ...
The ex-dividend date is the first date following the declaration of a dividend on which the buyer of a stock is not entitled to receive the next dividend payment. For calculation purposes, the number of days of ownership includes the day of disposition but not the day of acquisition. In the case of preferred stock, you must have held the stock ...
PFE Revenue (TTM) data by YCharts Pfizer's vaccine (Comirnaty) and treatment option (Paxlovid) combined for $56 billion in revenue in 2022. Those two products represented just $2.4 billion of ...
The ex-date or ex-dividend date represents the date on or after which a security is traded without a previously declared dividend or distribution. [1] The opening price on the ex-dividend date, in comparison to the previous closing price, can be expected to decrease by the amount of the dividend, although this change may be obscured by other ...
After this date the shares becomes ex dividend. Ex-dividend date – the day on which shares bought and sold no longer come attached with the right to be paid the most recently declared dividend. In the United States and many European countries, it is typically one trading day before the record date. This is an important date for any company ...
Pharmaceutical giant Pfizer (NYSE: PFE) stands out in this context. The company currently offers a mouthwatering 5.7% dividend yield -- the highest among major drug manufacturers and one of the ...
In September 2019, Pfizer initiated a study with the CDC Foundation to investigate the tracking of healthcare-associated infections, scheduled to run through to June 2023. [96] In December 2019, Pfizer awarded the CDC Foundation a further $1,948,482 to continue its cryptococcal disease screening and treatment research in nine African countries.